programas cribado cancer

ACTUALIZACIÓN BIBLIOGRÁFICA

Nota Bibliográfica

Esta Nota es una recopilación de publicaciones (artículos, informes, libros) sobre cribado de cáncer resultado de una revisión no sistemática de la literatura.

Podéis dirigir vuestros comentarios o sugerencias sobre la Nota a:

Josep A Espinás. Pla Director d'Oncología de Catalunya.
Correo electrónico: Esta dirección electrónica esta protegida contra spam bots. Necesita activar JavaScript para visualizarla

Nota blibliográfica cribado c próstata 2012-08

D'Amico AV, Smith MR. Clinical decisions. Screening for prostate cancer. N Engl J Med 2012 Aug 16;367(7):e11.  DOI: 10.1056/NEJMclde1209426 [doi]  PM:22894598
 
Heijnsdijk EAM, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, et al. Quality-of-Life Effects of Prostate-Specific Antigen Screening. New England Journal of Medicine 2012 Aug 15;367(7):595-605.  DOI: doi: 10.1056/NEJMoa1201637
http://dx.doi.org/10.1056/NEJMoa1201637
 
 Conclusions: The benefit of PSA screening was diminished by loss of QALYs owing to postdiagnosislong-term effects. Longer follow-up data from both the ERSPC and quality-of-lifeanalyses are essential before universal recommendations regarding screening can be made.
Sox HC. Quality of Life and Guidelines for PSA Screening editorial. New England Journal of Medicine 2012 Aug 15;367(7):669-71.  DOI: doi: 10.1056/NEJMe1207165
http://dx.doi.org/10.1056/NEJMe1207165
 
Wever EM, Hugosson J, Heijnsdijk EAM, Bangma CH, Draisma G, de Koning HJ. To be screened or not to be screened? Modeling the consequences of PSA screening for the individual. Br J Cancer 2012 Aug 21;107(5):778-84.  http://dx.doi.org/10.1038/bjc.2012.317
 
Conclusion: The decision to be screened should depend on personal preferences. The negative impact of screening might be reduced by screening men who are more willing to accept the side effects from treatment.

 

Nota bibliográfica cribado c próstata 2012-07

Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, Parnes H, et al. Screening for Prostate Cancer With Prostate-Specific Antigen Testing: American Society of Clinical Oncology Provisional Clinical Opinion . J Clin Oncol 2012 Jul 16.  DOI: 10.1200/JCO.2012.43.3441  http://jco.ascopubs.org/content/early/2012/07/16/JCO.2012.43.3441.abstract
 
On the basis of identified evidence and the expert opinion of the panel (Table 1 provides a description of how recommendations and evidence are rated): In men with a life expectancy 10 years,* it is recommended that physicians discuss with their patients whether PSA testing for prostate cancer screening is appropriate for them. PSA testing may save lives but is associated with harms, including complications, from unnecessary biopsy, surgery, or radiation treatment.Type and strength of recommendation. Evidence based: strong.Strength of evidence. For benefit, moderate; for harm, strong: based on five RCTs (and several cohort studies) with intermediate to high risk of bias, moderate follow-up, indirect data, inconsistent results, and limited data on subgroup populations.It is recommended that information written in lay language be available to clinicians and their patients to facilitate the discussion of the benefits and harms associated with PSA testing before the routine ordering of a PSA test.Type and strength of recommendation. Informal consensus: strong.Strength of evidence. Indeterminate: evidence was not systematically reviewed to inform this recommendation; however, randomized trials are available on the topic.*Calculation of life expectancy is based on a variety of individual factors and circumstances. A number of life expectancy calculators (eg, http://www.socialsecurity.gov/OACT/population/longevity.html) are available in the public domain; however, ASCO does not endorse any one calculator over another

The Lancet. Prostate cancer: send away the PSA?  editorial. Lancet 2012 Jul;380(9839):307.  DOI: doi: 10.1016/S0140-6736(12)61232-X  http://www.sciencedirect.com/science/article/pii/S014067361261232X

 

Nota bilbiográfica cribado c próstata 2012-06

 
To screen or not to screen for prostate cancer?editorial. Lancet 2012 Jun 2;379(9831):2024.  DOI: S0140-6736(12)60878-2 [pii];10.1016/S0140-6736(12)60878-2 [doi]
 
Carlsson S, Vickers AJ, Roobol M, Easthan J, Scardino P, Lilja H, et al. Prostate Cancer Screening: Facts, Statistics, and Interpretation in Response to the US Preventive Services Task Force Review Comment. J Clin Oncol 2012.  PM:22711853

   

Screening for prostate cancer

Andriole GL, Jr. Screening for prostate cancer. BMJ 2010;341:c4538.PMID:20843936

 

Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials

Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010;341:c4543. PMC2939952PMID:20843937

   

Página 5 de 14

balidea
web desarrollada y mantenida por :